Slingshot members are tracking this event:

Olumacostat glasaretil CLAREOS-1 Phase 3 clinical trial topline results in patients with acne vulgaris expected in the first half of 2018 -Did Not Meet Co-Primary Endpoints, Discontinued

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 05, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Olumacostat Glasaretil, Clareos-1, Phase 3